Full View

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

P Kaufmann, S Niglis, S Bruderer… - British Journal of …, 2015 - Wiley Online Library
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT‐333679. Methods This …
被引用次数：39 相关文章

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

P Kaufmann, S Niglis, S Bruderer, J Segrestaa… - British Journal of Clinical …, 2015 - infona.pl
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT‐333679. Methods This …

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

P Kaufmann, S Niglis, S Bruderer… - British Journal of …, 2015 - hero.epa.gov
AIMS: This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. METHODS …

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.

P Kaufmann, S Niglis, S Bruderer… - British Journal of …, 2015 - search.ebscohost.com
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. Methods This …
[HTML] nih.gov

[HTML][HTML] Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

P Kaufmann, S Niglis, S Bruderer… - British Journal of …, 2015 - ncbi.nlm.nih.gov
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. Methods This …

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.

P Kaufmann, S Niglis, S Bruderer… - British Journal of …, 2015 - europepmc.org
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. Methods This …

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

P Kaufmann, S Niglis, S Bruderer, J Segrestaa… - 2015 - pubmed.ncbi.nlm.nih.gov
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. Methods This …

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.

P Kaufmann, S Niglis, S Bruderer… - British Journal of …, 2015 - europepmc.org
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. Methods This …

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

P Kaufmann, S Niglis, S Bruderer, J Segrestaa… - British Journal of Clinical …, 2015 - infona.pl
Aims This study investigated the effect of a fixed dose combination of lopinavir/ritonavir on
the pharmacokinetics (PK) of selexipag and its active metabolite ACT‐333679. Methods This …